EntryPoint Capital’s Precigen PGEN Stock Holding History

EntryPoint Capital’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21,479	Closed	-$31.1K	–	1450
2024 Q1	$31.1K	Buy	+21,479	New	+$30.8K	0.03%	942

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EntryPoint Capital's PGEN Position: Q2 2024 in Review

EntryPoint Capital sold out of Precigen (PGEN) in Q2 2024, closing a stake of 21,479 shares — an estimated $31.1K sold.

EntryPoint Capital first reported a position in PGEN in Q1 2024 and held it in 1 quarter. The position peaked at $31.1K in Q1 2024. 130 funds tracked by Wall St. Rank hold PGEN as of Q2 2024.

EntryPoint Capital reported no remaining Precigen position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 21,479 Precigen shares in Q2 2024, an estimated $31.1K.
EntryPoint Capital first reported a position in Precigen in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's Precigen position peaked at $31.1K in Q1 2024.
130 funds tracked by Wall St. Rank held Precigen as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.